Pregnancy-specific 1l-glycoprotein in Breast Tumours
Author Information
Author(s): S. Sorensen, J. Andersen, T. Nqrgaard
Primary Institution: Department of Clinical Chemistry, Glostrup Hospital
Hypothesis
Can the determination of SP1 in serum and tumor tissue serve as a prognostic indicator for patients with malignant breast tumors?
Conclusion
Quantifying SP1 in serum or detecting it in tumor tissue appears to have little clinical value in managing breast cancer patients.
Supporting Evidence
- SP1 was detected in 37-76% of malignant breast tumors.
- Women with SP1 negative tumors had significantly longer survival times than those with SP1 positive tumors.
- Only 18% of malignant breast tumors showed SP1 reactivity.
Takeaway
The study looked at a protein called SP1 in women with breast tumors to see if it could help doctors decide on treatment, but it didn't turn out to be very useful.
Methodology
The study used a radioimmunoassay to measure SP1 levels in serum and an immunoperoxidase technique to detect SP1 in tumor tissue.
Limitations
The follow-up period was only 3 years, and the number of patients with SP1 positive tumors was too small for satisfactory statistical analysis.
Participant Demographics
113 women with suspected breast tumors, including 79 with benign and 34 with malignant tumors.
Statistical Information
Confidence Interval
95%
Want to read the original?
Access the complete publication on the publisher's website